Table II.
Demographics and clinical characteristics of all the 71 participants.
| Mean ± SD | |
|---|---|
| Age (years) | 33.4 ± 2.7 |
| BMI (kg/m2) | 25.8 ± 2.8 |
| Serum Day 3 FSH (mIU/mL) | 6.9 ± 2.3 |
| Serum Day 3 E2 (pmol/L) | 171.1 ± 40.8 |
| Antral follicle count by ultrasound | 15.9 ± 4.9 |
| Number of days of stimulation | 9.8 ± 3.3 |
| Total gonadotropin IUs per cycle | 3481.5 ± 956.5 |
| Serum peak E2 level (pmol/L) on day of hCG | 6689.2 ± 2892.3 |
| Number of oocytes retrieved | 10.3 ± 4.9 |
| Follicular fluid sRAGE (nmol/L) | 155.7 ± 62.3 |
| Follicular fluid 25-hydroxyvitamin D (nmol/L) | 95.1 ± 26 |
| Follicular fluid VDBP (nmol/L) | 4553.4 ± 1481.3 |
| Follicular fluid pentosidine (nmol/L) | 20.3 ± 18.6 |
| Follicular fluid CML (μmol/L) | 0.34 ± 0.1 |
| Follicular fluid total testosterone (nmol/L) | 9.7 ± 18.9 |
| Follicular fluid free testosterone (nmol/L) | 1.2 ± 2.5 |
| Follicular fluid SHBG (nmol/L) | 1297.9 ± 466.3 |
| Follicular fluid insulin (μIU/mL) | 5.9 ± 6.9 |
| Follicular fluid glucose (mmol/L) | 2.92 ± 0.82 |
E2, estradiol; sRAGE, soluble receptor for advanced glycation end products; CML, N-(carboxymethyl) lysine; SHBG, sex hormone binding globulin.